Vasculogenic Mimicry of HT1080 Tumour Cells In Vivo: Critical Role of HIF-1α-Neuropilin-1 Axis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Misra, Roli M ^a   Bajaj, Manmohan S ^a   Kale, Vaijayanti P ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; NEUROPILIN 1; OCTAMER TRANSCRIPTION FACTOR 4; RIBOSOME RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX2; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ERYTHROCYTE; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; DISULFIDES; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLE ALKALOIDS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; NEOPLASMS, FIBROUS TISSUE; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; OCTAMER TRANSCRIPTION FACTOR-3; OXYGEN; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84869777262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050153     Document Type: Article

References (79)

1. Carmeliet P, Jain RK, (2000) Angiogenesis in cancer and other Diseases. Nature. 407(6801): 249-257.
2. Folkman J, (1995) Clinical applications of research on angiogenesis. N Engl J Med. 333(26): 1757-1763.
3. Weis SM, Cheresh DA, (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 17(11): 1359-1370.
4. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795): 536-540.
5. Alitalo K, Carmeliet P, (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1(3): 219-227.
6. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. (1999) Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry. Am J Pathol 155(3): 739-752.
7. Van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, et al. (2004) Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 96(19): 1473-1477.
8. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW, (2010) Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 1806(1): 18-28.
9. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, et al. (2012) Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 181(4): 1115-1125.
10. Fong GH, (2008) Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 11(2): 121-140.
11. Harris AL, (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47.
12. Keith B, Simon MC, (2007) Hypoxia-inducible factors, stem cells and cancer. Cell. 129(3): 465-472.
13. Rankin EB, Giaccia AJ, (2008) The role of hypoxia-inducible factors in tumorgenesis. Cell Death Differ. 15(4): 678-685.
14. Patel-Hett S, D'Amore PA, (2011) Signal transduction in vasculogenesis and developmental angiogenesis. Int J Dev Biol. 55(4-5): 353-363.
15. Ferrara N, Alitalo K, (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 5(12): 1359-1364.
16. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 40(5): 499-507.
17. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell stem cell. 2(4): 333-344.
18. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71(13): 4640-4652.
19. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, et al. (2002) c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16(19): 2530-2543.
20. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV, (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 27(21): 7381-7393.
21. Pellet-Many C, Frankel P, Evans IM, Herzog B, Jünemann-Ramírez M, et al. (2011) Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migrationand signalling via p130Cas. Biochem J. 435(3): 609-618.
22. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D, (2003) Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem. 278(49): 48848-48860.
23. Geretti E, Shimizu A, Klagsbrun M, (2008) Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 11(1): 31-39.
24. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, et al. (2004) Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 123(6): 1151-1161.
25. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M, (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J.Cell Biochem. 85 (2): 357-368.
26. Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda A, et al. (2003) Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer. 88(5): 796-802.
27. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, et al. (2005) Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res. 65(9): 3664-3670.
28. Cao Y, E G, Wang E, Pal K, Dutta SK, et al. (2012) VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72(16): 3912-3918.
29. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, et al. (2001) Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 84(8): 1070-1075.
30. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D'Amore PA, (2005) Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 65(13): 5881-5889.
31. Ke J, Liu Y, Long X, Li J, Fang W, et al. (2007) Up-regulation of vascular endothelial growth factor in synovial fibroblasts from human temporo mandibular joint by hypoxia. J Oral Pathol Med. 36(5): 290-296.
32. Li W, Keller G, (2000) VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J Cell Sci. 113 (Pt 9): 1525-1534.
33. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, et al. (2010) Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 285(8): 5532-5540.
34. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, et al. (1999) An in vitro model of angiogenesis, basic features. Angiogenesis. 3(4): 335-344.
35. Van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, et al. (2005) Tumor cell plasticity in ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 65(24): 11520-11528.
36. Zhu P, Ning Y, Yao L, Chen M, Xu C (2010) The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 29 (124).
37. Arsham AM, Plas DR, Thompson CB, Simon MC, (2004) Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 64(10): 3500-3507.
38. Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, et al. (2007) Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer. 7: 213.
39. Brusselmans K, Bono F, Collen D, Herbert JM, Carmeliet P, et al. (2005) A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem. 280(5): 3493-3499.
40. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, et al. (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer cell 13(4): 331-342.
41. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, et al. (2008) Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 34(5): 1381-1386.
42. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer. 102(5): 789-795.
43. Pugh CW, Ratcliffe PJ, (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 9(6): 677-684.
44. Warnecke C, Griethe W, Weidemann A, Jürgensen JS, Willam C, et al. (2003) Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 17(9): 1186-1188.
45. Rapisarda A, Melillo G, (2012) Overcoming disappointing results with antiangiogenic therapy by targetinghypoxia. Nat Rev Clin Oncol. 9(7): 378-390.
46. Kaya M, Wada T, Nagoya S, Kawaguchi S, Yamashita T, et al. (2001) TNP-470 suppresses the tumorigenicity of HT1080 fibrosarcoma tumor through the inhibition of VEGF secretion from the tumor cells. Sarcoma. 5(4): 197-202.
47. Lee HJ, Kim SA, Lee HJ, Jeong SJ, Han I, et al. (2010) Paeonol Oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS ONE 5(8): e12358.
48. Weng C, Dong H, Chen G, Zhai Y, Bai R, et al. (2012) miR-409-3p inhibits HT1080 cell proliferation, vascularization and metastasis bytargeting angiogenin. Cancer Lett. 323(2): 171-179.
49. McDonald DM, Munn L, Jain R, (2000) Vasculogenic Mimicry: How convincing, How novel, and How Significant? Am. J. Pathology 156(2): 383-388.
50. Sanz L, Feijóo M, Blanco B, Serrano A, Alvarez-Vallina L, (2003) Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. Cancer Immunol Immunother. 52(10): 643-647.
51. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M, (2006) Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res. 312(5): 584-593.
52. Uniewicz KA, Cross MJ, Fernig DG, (2011) Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis. J Biol Chem. 286(1): 12-23.
53. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M, (2000) Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14(15): 2532-2539.
54. Glinka Y, Mohammed N, Subramaniam V, Jothy S, Prud'homme GJ, (2012) Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NFκB activation and tumor sphere formation. Biochem Biophys Res Commun. 425(4): 775-780.
55. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, et al. (2012) Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. (3): 507-520.
56. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, et al. (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 478(7369): 399-403.
57. Papatriantafyllou M (2012) T cells: Neuropilin 1- distinguishing T(Reg) cell subsets. Nat Rev Immunol. doi: 10.1038/nri3323.
58. Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, et al. (2012) Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med. DOI: 10.1084/jem.20111497.
59. Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, et al. (2012) Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Res. 72(16): 4047-4059.
60. Rizzolio S, Rabinoviz N, Rainero E, Lanzetti L, Serini G, et al. (2012) Neuropilin-1 dependent regulation of EGF-Receptor signaling. Cancer Res. doi: 10.1158/0008-5472.
61. Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, et al. (2004) Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol. 164(6): 2139-2151.
62. Li X, Tang T, Lu X, Zhou H, Huang Y, (2011) RNA interference targeting NRP-1 inhibits human glioma cell proliferation andenhances cell apoptosis. Mol Med Report. 4(6): 1261-1266.
63. Samuel S, Gaur P, Fan F, Xia L, Gray MJ, et al. (2011) Neuropilin-2 mediated β-catenin signaling and survival in human gastro-intestinalcancer cell lines. PLoS One. 6(10): e23208.
64. Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, et al. (2004) Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Mol Vis. 10: 341-350.
65. Jogi A, Vallon-Christersson J, Holmquist L, Axelson H, Borg A, et al. (2004) Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res. 295 (2): 469-487.
66. Bartsch G Jr, Eggert K, Soker S, Bokemeyer C, Hautmann R, et al. (2008) Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma, J Urol. 179(1): 326-332.
67. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, et al. (2007) Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 13(16): 4759-4768.
68. Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, et al. (2007) Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 28(12): 2397-2402.
69. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, et al. (2007) Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol. 366(3): 815-829.
70. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, et al. (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 53(5): 2215-2226.
71. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, et al. (2007) Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 27(3): 912-925.
72. Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, et al. (2007) Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma. 48(10): 1997-2007.
73. Rushing EC, Stine MJ, Hahn SJ, Shea S, Eller MS, et al. (2012) Neuropilin-2: a novel biomarker for malignant melanoma? Hum Pathol. 43(3): 381-389.
74. Coma S, Shimizu A, Klagsbrun M, (2011) Hypoxia induces tumor and endothelial cell migration in a Semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor Neuropilin 2. Cell Adh Migr. 5 (3): 266-275.
75. Kawanami D, Mahabeleshwar GH, Lin Z, Atkins GB, Hamik A, et al. (2009) Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium. J Biol Chem. 284(31): 20522-20530.
76. Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, et al. (2012) miR 103/107 promote metastasis of colorectal cancer by targeting the metastasissuppressors DAPK and KLF4. Cancer Res. 72(14): 3631-3641.
77. Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL, (2004) c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 64(18): 6563-6570.
78. Kale VP, Vaidya AA, (2004) Molecular mechanisms behind the dose-dependent differential activation of MAPK pathways induced by transforming growth factor-beta1 in hematopoietic cells. Stem Cells Dev. 13(5): 536-547.
79. Williams CK, Li JL, Murga M, Harris AL, Tosato G, (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 107(3): 931-939.